Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.54 |
| ▸ | CA2 | P00918 | 6/20 | 0.54 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546298 | 0.96 | CA1 (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15077172 | 0.91 | NOTUM (0.68) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1204263 | 0.88 | NOTUM (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1188779 | 0.88 | CA1 (0.68) | CA1CA2CA12CA7CA9 | |
| SCHEMBL14508886 | 0.88 | CNR2 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL545464 | 0.88 | NOTUM (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1530343 | 0.87 | NOTUM (0.46) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1530374 | 0.87 | NOTUM (0.46) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3737467 | 0.87 | NOTUM (0.73) | CA1CA2CA12CA7CA9 | |
| SCHEMBL545730 | 0.87 | NOTUM (0.46) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| WO-2000029023-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| CN-106459114-B | Organic iridium complex for organic electroluminescent device | 田中贵金属工业株式会社 | 2019-08-27 | — | — | CN | disclosed |
| EP-3187503-B1 | ORGANOIRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENT | TANAKA PRECIOUS METAL IND (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-9859511-B2 | Organoiridium complex for organic electroluminescent elements | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2018-01-02 | — | — | US | disclosed |
| US-9859511-B2 | Organoiridium complex for organic electroluminescent elements | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2018-01-02 | — | — | US | disclosed |
| US-9793499-B2 | Organic iridium complex for organic electroluminescent element | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9793499-B2 | Organic iridium complex for organic electroluminescent element | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9793499-B2 | Organic iridium complex for organic electroluminescent element | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-10-17 | — | — | US | disclosed |
| US-20170237021-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-08-17 | — | — | US | disclosed |
| EP-0675153-B1 | Process for the preparation of star-shaped polymers | SHELL INT RESEARCH (NL) | 2001-06-13 | — | — | EP | disclosed |
| EP-1099717-A2 | Star-shaped polymers | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| CN-1115321-A | Star-shaped polymers | SHELL INT RESEARCH (NL) | 1996-01-24 | — | — | CN | disclosed |
| US-5458796-A | Synthesis of polyisobutylene star-branched polymers via living carbocationic polymerization | SHELL OIL COMPANY (US) | 1995-10-17 | — | — | US | disclosed |
| EP-0675153-A1 | Star-shaped polymers | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1995-10-04 | — | — | EP | disclosed |
| US-5420343-A | ANTIINFLAMMATORY AGENTS; CYCLOOXYGENASE INHIBITORS | G. D. SEARLE & CO. (US) | 1995-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170237021-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | L1CAM, ETFA, TTI2 | CA1 3624/4885CA2 3190/4885CA12 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.